Folgen
Jacob S. Aday
Jacob S. Aday
University of Michigan
Bestätigte E-Mail-Adresse bei umich.edu - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
AK Schlag, JS Aday, I Salam, JC Neill, DJ Nutt
Journal of Psychopharmacology 36 (3), 258-272, 2022
2522022
Long-term effects of psychedelic drugs: A systematic review
JS Aday, CM Mitzkovitz, EK Bloesch, CC Davoli, AK Davis
Neuroscience & Biobehavioral Reviews 113, 179-189, 2020
2462020
Great Expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials
JS Aday, BD Heifets, SD Pratscher, E Bradley, R Rosen, J Woolley
Psychopharmacology, 2022
1692022
Predicting reactions to psychedelic drugs: A systematic review of states and traits related to acute drug effects
JS Aday, AK Davis, CM Mitzkovitz, EK Bloesch, CC Davoli
ACS Pharmacology & Translational Science, 2021
1672021
2019: A year of expansion in psychedelic research, industry, and deregulation
JS Aday, EK Bloesch, CC Davoli
Drug Science, Policy and Law 6, 2050324520974484, 2020
662020
2018: A watershed year for psychedelic science
JS Aday, CC Davoli, EK Bloesch
Drug Science, Policy and Law, 2019
422019
Extended testing with the dot-probe task increases test–retest reliability and validity
JS Aday, JM Carlson
Cognitive Processing 20 (1), 65-72, 2019
382019
Psychedelics and virtual reality: Parallels and applications
JS Aday, CC Davoli, EK Bloesch
Therapeutic Advances in Psychopharmacology, 2020
362020
Neural mechanisms of emotions and affect
JS Aday, W Rizer, J Carlson
Emotions and Affect in Human Factors & Human-Computer Interaction 1, 27-87, 2017
322017
Emerging Challenges for Psychedelic Therapy
JS Aday, RL Carhart-Harris, JD Woolley
JAMA Psychiatry, 2023
292023
Neurotensin NTS1 and NTS2 receptor agonists produce anxiolytic-like effects in the 22-kHz ultrasonic vocalization model in rats
F Steele, S Whitehouse, JS Aday, A Prus
Brain Research, 2017
292017
Psychedelic commercialization: A wide-spanning overview of the emerging psychedelic industry
JS Aday, BS Barnett, D Grossman, KS Murnane, CD Nichols, ...
Psychedelic Medicine 1 (3), 150-165, 2023
282023
Personal psychedelic use is common among a sample of psychedelic therapists: Implications for research and practice
JS Aday, Z Skiles, N Eaton, L Fredenburg, M Pleet, J Mantia, ER Bradley, ...
Psychedelic Medicine, 2023
282023
Psychedelic drugs and perception: A narrative review of the first era of research
JS Aday, JR Wood, EK Bloesch, CC Davoli
Reviews in the Neurosciences, 2021
282021
Beyond LSD: A broader psychedelic zeitgeist during the early to mid-20th century
JS Aday, EK Bloesch, CC Davoli
Journal of Psychoactive Drugs, 1-8, 2019
262019
Can psychedelic drugs attenuate age-related changes in cognition and affect?
JS Aday, EK Bloesch, CC Davoli
Journal of Cognitive Enhancement, 1-9, 2019
252019
Temporal dynamics in attention bias: Effects of sex differences, task timing parameters, and stimulus valence
JM Carlson, JS Aday, D Rubin
Cognition and Emotion 33 (6), 1271-1276, 2019
212019
Structural MRI-based measures of neuroplasticity in an extended amygdala network as a target for attention bias modification treatment outcome
JS Aday, JM Carlson
Medical Hypotheses 109, 6-16, 2017
212017
Debunking the myth of ‘Blue Mondays’: No evidence of affect drop after taking clinical MDMA
B Sessa, JS Aday, S O’Brien, HV Curran, F Measham, L Higbed, DJ Nutt
Journal of Psychopharmacology 36 (3), 360-367, 2022
152022
In the presence of conflicting gaze cues, fearful expression and eye-size guide attention
JM Carlson, JS Aday
Cognition and Emotion 32 (6), 1178-1188, 2018
152018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20